Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Treon

Showing results (281-290 of 323) with videos related to

Pageof 33
Sort By:
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Blood|February 24, 2016
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemiaAldo M Roccaro, Antonio Sacco, Jiantao Shi, et al.
ACS Chemical Biology|February 22, 2014
Discovery of a potent, covalent BTK inhibitor for B-cell lymphomaHong Wu, Wenchao Wang, Feiyang Liu, et al.
Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Multiple myelomaKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Pageof 33

Showing results (281-290 of 323) with videos related to

Sort By:
Pageof 33
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Blood|February 24, 2016
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemiaAldo M Roccaro, Antonio Sacco, Jiantao Shi, et al.
ACS Chemical Biology|February 22, 2014
Discovery of a potent, covalent BTK inhibitor for B-cell lymphomaHong Wu, Wenchao Wang, Feiyang Liu, et al.
Nature Communications|February 10, 2025
Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom's MacroglobulinemiaRomanos Sklavenitis-Pistofidis, Yoshinobu Konishi, Daniel Heilpern-Mallory, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Multiple myelomaKenneth C Anderson, Melissa Alsina, William Bensinger, et al.
Clinical Lymphoma & Myeloma|October 13, 2007
Novel agents in the treatment of Waldenström's macroglobulinemiaSteven P Treon, Evdoxia Hatjiharissi, Xavier Leleu, et al.
Pageof 33